Endocrine Journal
Our official Japanese journal "Naibunpigaku Zasshi" was first issued in 1925 and renamed as "Nihon Naibunpigaku-kai Zasshi" in 1927. In 1954 the first issue of English official journal "Endocrinologia Japonica" was published continuing to Volume 39 in 1992 and then renamed as the present "Endocrine Journal" from Volume 40 in 1993.

Visit Journal Website.
もっと読む
収録数 6,914本
(更新日 2025/07/31)
Online ISSN : 1348-4540
Print ISSN : 0918-8959
ISSN-L : 0918-8959
1.9
2023 Journal Impact Factor (JIF)
ジャーナル 査読 オープンアクセス HTML 早期公開
DOAJ Scopus Pubmed
おすすめ記事
72 巻 (2025) 7 号 p. 751-764
Physiology and clinical applications of GIP もっと読む
編集者のコメント

Recommendation from the Editor in Chief
Exactly the insightful story of incretin hormone, glucose-dependent insulinotropic hormone (GIP) has long attracted broad attention among basic and clinical fields of endocrinology. A series of drugs co-stimulating multiple gut hormone receptors are now applied in clinics of type 2 diabetes, obesity disease and relevant metabolic diseases. In this issue, Professor Emeritus of Kyoto University, Dr. Nobuya Inagaki and his colleague, world-renowned pioneering scientists of GIP research, contribute a sophisticated and cutting-edge review on update of physiology and clinical applications of GIP. Our editorial team has a firm belief that all readers will definitely be fascinated and moved by the full of academic incense contained.

72 巻 (2025) 6 号 p. 649-662
Hypopituitarism: genetic, developmental, and acquired etiologies with a focus on the emerging concept of autoimmune hypophysitis もっと読む
編集者のコメント

Recommendation from the Editor in Chief
Amazing progress in research and clinics on molecular pathophysiology of hypopituitarism has recently attracted broad interest from endocrinologists. Particularly noteworthy is the great contribution of Japanese scientists to such an accomplishment. In the June issue, Dr. Hironori Bando and colleague at Kobe University provide us with cutting-edge, comprehensive review article on the update of hypopituitarism with a specific emphasis on paraneoplastic autoimmune hypopituitarism.

72 巻 (2025) 5 号 p. 463-473
Management of Cushing’s disease in the initial phase~From detection to surgery~ もっと読む
編集者のコメント

Recommendation from the Editor in Chief
As well known, Cushing’s disease is a symbolic endocrine disorder in which a variety of basic, clinical, diagnostic and therapeutic insights are crystallized. Unexpectedly, however, there have still been unsolved issues in early diagnosis, interpretation for endocrinologic testing, and preoperative management. To better understand the latest situation around the clinics on Cushing’s disease, Dr. Hidenori Fukuoka seasonably provides a fascinating and comprehensive overview in the May Issue. Our editorial team has a firm belief that all readers will definitely be satisfied by the empirical knowledge of an expert endocrinologist.

72 巻 (2025) 4 号 p. 341-353
Ghrelin–LEAP2 interactions along the stomach–liver axis もっと読む
編集者のコメント

Recommendation from the Editor in Chief
There are examples where distinct two peptide ligands respectively act as an agonist and antagonist on the same receptor. To my knowledge, the best-known one is related with the story that alpha-MSH and agouti-related peptide (AgRP) act on the melanocrtin-4 receptor (MC4R) as an agonist and antagonist, thereby minutely regulating appetite and body weight. In this issue, Dr. Katsuya Sakai and Professor Masamitsu Nakazato, a world-renowned physician scientist on research of orexigenic hormone ghrelin, provide us with well-organized, fabulous review article focusing on the dynamic interaction between ghrelin and LEAP-2 (liver-expressed antimicrobial peptide 2) in terms of stomach-liver axis-driven appetite control. Indeed, ghrelin and LEAP-2 respectively act as an agonist and antagonist on the same receptor, GHSR (growth hormone secretagogue receptor). Our editorial team has a firm belief that all readers are surely motivated by the real deal of authentic endocrinology and cutting-edge medicine on GPCR signal transduction in this article.

72 巻 (2025) 3 号 p. 259-272
Epidermal growth factor receptor contributes to indirect regulation of skeletal muscle mass by androgen もっと読む
編集者のコメント

Recommendation from the Editor in Chief
Reflecting an expeditious increase in elder patients with sarcopenia notably in industrialized countries, endocrinologic research on molecular basis of muscle mass and strength has attracted great attention in both academic and clinical fields. In this issue, Dr. Tomoya Onishi, Professor Yuuki Imai and colleague provide fresh insight into unexpected interplay between androgens and epidermal growth factor receptor (EGFR) EGFR in the molecular pathophysiology of shrinkage of muscle mass. This excellent article provides all endocrinologists with updated viewpoint of sarcopenia science.

すべてのおすすめ記事を見る
最新号のすべての記事を見る
月間アクセス数ランキング (2025年06月)
このページを共有する
過去の巻号を選ぶ
feedback
Top